AIMS: Secretory carcinoma (SC) (synonym: mammary analogue secretory carcinoma) is a low-grade salivary gland tumour that occurs in both major and minor salivary glands. SC is known for its wide morphological, architectural and immunohistochemical spectrum, which overlaps with those of several salivary gland neoplasms, including acinic cell carcinoma (AciCC) and intercalated duct-type intraductal carcinoma (IDC) in major salivary glands, and polymorphous adenocarcinoma (PAC) in minor salivary glands. These tumours share with SC some morphological features and SOX10 immunoreactivity; also, with the exception of AciCC, they all coexpress S100 and mammaglobin. METHODS AND RESULTS: We compared MUC4 and mammaglobin expression in 125 salivary gland carcinomas (54 genetically confirmed SCs, 20 AciCCs, 21 PACs, and 30 IDCs) to evaluate the potential of these two markers to differentiate these entities. Moderate to strong diffuse MUC4 positivity was detected in 49 SCs (90.7%), as compared with none of the IDCs and PACs. In contrast, mammaglobin was frequently expressed in SCs (30 of 36 cases; 83.3%), IDCs (24/28; 85.7%), and PACs (7/19; 36.8%). Two of three high-grade SCs lost MUC4 expression in the high-grade tumour component. No significant correlation was found between MUC4 expression and the fusion variant in SC (ETV6-NTRK versus non-ETV6-NTRK). CONCLUSION: The results of our study identify MUC4 as a sensitive (90.7%) and specific (100%) marker for SC, with high positive (100%) and negative (93.4%) predictive values. Thus, MUC4 may be used as a surrogate for SC in limited biopsy material and in cases with equivocal morphology.

Department of Laboratory Medicine Unit of Anatomical Pathology Pisa University Hospital Pisa Italy

Department of Pathology Faculty of Medicine in Plzen Charles University Plzen Czech Republic

Department of Translational Research School of Medicine University of Pisa Pisa Italy

Institute of Pathology Friedrich Alexander University Erlangen Nürnberg University Hospital Erlangen Germany

The Molecular Foundry Lawrence Berkeley National Laboratory Berkeley CA USA

Unit of Histopathology and Molecular Diagnostics Careggi University Hospital Florence Italy

Zobrazit více v PubMed

Skalova A, Vanecek T, Sima R et al. Mammary analogue secretory carcinoma of salivary glands, containing the ETV6-NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity. Am. J. Surg. Pathol. 2010; 34; 599-608.

Skalova A. Mammary analogue secretory carcinoma of salivary gland origin: an update and expanded morphologic and immunohistochemical spectrum of recently described entity. Head Neck Pathol. 2013; 7(Suppl. 1); S30-S36.

Connor A, Perez-Ordonez B, Shago M, Skalova A, Weinreb I. Mammary analog secretory carcinoma of salivary gland origin with the ETV6 gene rearrangement by FISH: expanded morphologic and immunohistochemical spectrum of a recently described entity. Am. J. Surg. Pathol. 2012; 36; 27-34.

Skalova A, Vanecek T, Majewska H et al. Mammary analogue secretory carcinoma of salivary glands with high-grade transformation: report of 3 cases with the ETV6-NTRK3 gene fusion and analysis of TP53, β-catenin, EGFR, and CCND1 genes. Am. J. Surg. Pathol. 2014; 38; 23-33.

Luo W, Lindley SW, Lindley PH, Krempl GA, Seethala RR, Fung KM. Mammary analog secretory carcinoma of salivary gland with high-grade histology arising in hard palate, report of a case and review of literature. Int. J. Clin. Exp. Pathol. 2014; 7; 9008-9022.

Majewska H, Skalova A, Stodulski D et al. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. Virchows Arch. 2015; 466; 245-254.

Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M. Characterization of mammary analogue secretory carcinoma of the salivary gland: discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. Hum. Pathol. 2015; 46; 94-103.

Skalova A, Vanecek T, Martinek P et al. Molecular profiling of mammary analog secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation: report of 10 cases. Am. J. Surg. Pathol. 2018; 42; 234-246.

Rooper LM, Karantanos T, Ning Y, Bishop JA, Gordon SW, Kang H. Salivary secretory carcinoma with a novel ETV6-MET fusion: expanding the molecular spectrum of a recently described entity. Am. J. Surg. Pathol. 2018; 42; 1121-1126.

Black M, Liu CZ, Onozato M et al. Concurrent identification of novel EGFR-SEPT14 fusion and ETV6-RET fusion in secretory carcinoma of the salivary gland. Head Neck Pathol. 2020; 14; 817-821.

Skálová A, Banečkova M, Thompson LDR et al. Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion. Am. J. Surg. Pathol. 2020; 44; 1295-1307.

Davies JR, Herrmann A, Russell W, Svitacheva N, Wickstrom C, Carlstedt I. Respiratory tract mucins: structure and expression patterns. Novartis Found. Symp. 2002; 248; 76-88; discussion 88-93, 277-282.

Seregni E, Botti C, Massaron S et al. Structure, function and gene expression of epithelial mucins. Tumori 1997; 83; 625-632.

Offner GD, Troxler RF. Heterogeneity of high-molecular-weight human salivary mucins. Adv. Dent. Res. 2000; 14; 69-75.

Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am. J. Clin. Pathol. 2004; 122; 61-69.

Ho SB, Niehans GA, Lyftogt C et al. Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993; 53; 641-651.

Audie JP, Janin A, Porchet N, Copin MC, Gosselin B, Aubert JP. Expression of human mucin genes in respiratory, digestive, and reproductive tracts ascertained by in situ hybridization. J. Histochem. Cytochem. 1993; 41; 1479-1485.

Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat. Rev. Cancer 2004; 4; 45-60.

Liu B, Offner GD, Nunes DP, Oppenheim FG, Troxler RF. MUC4 is a major component of salivary mucin MG1 secreted by the human submandibular gland. Biochem. Biophys. Res. Commun. 1998; 250; 757-761.

Alos L, Lujan B, Castillo M et al. Expression of membrane-bound mucins (MUC1 and MUC4) and secreted mucins (MUC2, MUC5AC, MUC5B, MUC6 and MUC7) in mucoepidermoid carcinomas of salivary glands. Am. J. Surg. Pathol. 2005; 29; 806-813.

Li P, Arango ME, Perez RE et al. Expression and localization of immunoreactive-sialomucin complex (Muc4) in salivary glands. Tissue Cell 2001; 33; 111-118.

Weed DT, Gomez-Fernandez C, Bonfante E et al. MUC4 (sialomucin complex) expression in salivary gland tumors and squamous cell carcinoma of the upper aerodigestive tract. Otolaryngol. Head Neck Surg. 2001; 124; 127-141.

Weed DT, Gomez-Fernandez C, Pacheco J et al. MUC4 and ERBB2 expression in major and minor salivary gland mucoepidermoid carcinoma. Head Neck 2004; 26; 353-364.

Hamada T, Matsukita S, Goto M et al. Mucin expression in pleomorphic adenoma of salivary gland: a potential role for MUC1 as a marker to predict recurrence. J. Clin. Pathol. 2004; 57; 813-821.

Lanzel EA, Pourian A, Sousa Melo SL, Brogden KA, Hellstein JW. Expression of membrane-bound mucins and p63 in distinguishing mucoepidermoid carcinoma from papillary cystadenoma. Head Neck Pathol. 2016; 10; 521-526.

Kusafuka K, Itoh H, Sugiyama C, Nakajima T. Low-grade salivary duct carcinoma of the parotid gland: report of a case with immunohistochemical analysis. Med. Mol. Morphol. 2010; 43; 178-184.

Bissinger O, Gotz C, Kolk A et al. Mammary analogue secretory carcinoma of salivary glands: diagnostic pitfall with distinct immunohistochemical profile and molecular features. Rare Tumors 2017; 9; 7162.

Khurram SA, Sultan-Khan J, Atkey N, Speight PM. Cytogenetic and immunohistochemical characterization of mammary analogue secretory carcinoma of salivary glands. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. 2016; 122; 731-742.

Luk PP, Selinger CI, Eviston TJ et al. Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics. Pathology 2015; 47; 659-666.

Agaimy A, Tögel L, Haller F, Zenk J, Hornung J, Märkl B. YAP1-NUTM1 gene fusion in porocarcinoma of the external auditory canal. Head Neck Pathol. 2020. E-pub ahead of print, 20 May.

Baneckova M, Agaimy A, Andreasen S et al. Mammary analog secretory carcinoma of the nasal cavity: characterization of 2 cases and their distinction from other low-grade sinonasal adenocarcinomas. Am. J. Surg. Pathol. 2018; 42; 735-743.

Skalova A, Ptakova N, Santana T et al. NCOA4-RET and TRIM27-RET are characteristic gene fusions in salivary intraductal carcinoma, including invasive and metastatic tumors: is ‘intraductal’ correct? Am. J. Surg. Pathol. 2019; 43; 1303-1313.

Baghai F, Yazdani F, Etebarian A, Garajei A, Skalova A. Clinicopathologic and molecular characterization of mammary analogue secretory carcinoma of salivary gland origin. Pathol. Res. Pract. 2017; 213; 1112-1118.

Shah AA, Wenig BM, LeGallo RD, Mills SE, Stelow EB. Morphology in conjunction with immunohistochemistry is sufficient for the diagnosis of mammary analogue secretory carcinoma. Head Neck Pathol. 2015; 9; 85-95.

Montalvo N, Galarza D, Redroban L. Secretory carcinoma of the parotid: making the correct diagnosis of a rare salivary gland carcinoma when molecular biology testing is not available. Case Rep. Pathol. 2019; 2019; 5103496.

Delgado R, Klimstra D, Albores-Saavedra J. Low grade salivary duct carcinoma. A distinctive variant with a low grade histology and a predominant intraductal growth pattern. Cancer 1996; 78; 958-967.

Giovacchini F, Bensi C, Belli S et al. Low-grade intraductal carcinoma of salivary glands: a systematic review of this rare entity. J. Oral Biol. Craniofac. Res. 2019; 9; 96-110.

Brandwein-Gensler M, Hille J, Wang BY et al. Low-grade salivary duct carcinoma: description of 16 cases. Am. J. Surg. Pathol. 2004; 28; 1040-1044.

Weinreb I, Seethala RR, Hunt JL, Chetty R, Dardick I, Perez-Ordonez B. Intercalated duct lesions of salivary gland: a morphologic spectrum from hyperplasia to adenoma. Am. J. Surg. Pathol. 2009; 33; 1322-1329.

Nishijima T, Yamamoto H, Nakano T et al. Low-grade intraductal carcinoma (low-grade cribriform cystadenocarcinoma) with tumor-associated lymphoid proliferation of parotid gland. Pathol. Res. Pract. 2017; 213; 706-709.

Hsieh MS, Chou YH, Yeh SJ, Chang YL. Papillary-cystic pattern is characteristic in mammary analogue secretory carcinomas but is rarely observed in acinic cell carcinomas of the salivary gland. Virchows Arch. 2015; 467; 145-153.

Bishop JA, Yonescu R, Batista D, Eisele DW, Westra WH. Most nonparotid ‘acinic cell carcinomas’ represent mammary analog secretory carcinomas. Am. J. Surg. Pathol. 2013; 37; 1053-1057.

Naous R, Zhang S, Valente A, Stemmer M, Khurana KK. Utility of immunohistochemistry and ETV6 (12p13) gene rearrangement in identifying secretory carcinoma of salivary gland among previously diagnosed cases of acinic cell carcinoma. Pathol. Res. Int. 2017; 2017; 1497023.

Regezi JA, Zarbo RJ, Stewart JC, Courtney RM. Polymorphous low-grade adenocarcinoma of minor salivary gland. A comparative histologic and immunohistochemical study. Oral Surg. Oral Med. Oral Pathol. 1991; 71; 469-475.

Gonzalez-Garcia R, Rodriguez-Campo FJ, Munoz-Guerra MF, Nam-Cha SH, Sastre-Perez J, Naval-Gias L. Polymorphous low-grade adenocarcinoma of the palate: report of cases. Auris Nasus Larynx 2005; 32; 275-280.

Batsakis JG, Pinkston GR, Luna MA, Byers RM, Sciubba JJ, Tillery GW. Adenocarcinomas of the oral cavity: a clinicopathologic study of terminal duct carcinomas. J. Laryngol. Otol. 1983; 97; 825-835.

Montalli VA, Passador-Santos F, Martinez EF et al. Mammaglobin and DOG-1 expression in polymorphous low-grade adenocarcinoma: an appraisal of its origin and morphology. J. Oral Pathol. Med. 2017; 46; 182-187.

Patel KR, Solomon IH, El-Mofty SK, Lewis JS Jr, Chernock RD. Mammaglobin and S-100 immunoreactivity in salivary gland carcinomas other than mammary analogue secretory carcinoma. Hum. Pathol. 2013; 44; 2501-2508.

Hung YP, Jo VY, Hornick JL. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma. Histopathology 2019; 75; 54-62.

Bell D, Ferrarotto R, Liang L et al. Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. Virchows Arch. 2020; 476; 295-305.

Xu B, Haroon Al Rasheed MR, Antonescu CR et al. Pan-Trk immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion. Histopathology 2020; 76; 375-382.

Haller F, Skalova A, Ihrler S et al. Nuclear NR4A3 immunostaining is a specific and sensitive novel marker for acinic cell carcinoma of the salivary glands. Am. J. Surg. Pathol. 2019; 43; 1264-1272.